JPWO2019016109A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019016109A5 JPWO2019016109A5 JP2020502446A JP2020502446A JPWO2019016109A5 JP WO2019016109 A5 JPWO2019016109 A5 JP WO2019016109A5 JP 2020502446 A JP2020502446 A JP 2020502446A JP 2020502446 A JP2020502446 A JP 2020502446A JP WO2019016109 A5 JPWO2019016109 A5 JP WO2019016109A5
- Authority
- JP
- Japan
- Prior art keywords
- infection
- days
- primary
- primary infection
- onset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 description 9
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Description
本発明において、二次感染症とは、一次感染症及び／又は炎症及び／又は術後に起こり得るあらゆる感染症を意味する。例えば、一次感染症の発症から１～２８日後に発生する、例えば、一次感染症の発症から５～１２日後に発生する感染症であり得る。また、例えば、一次感染症の終了から１～２１日後、例えば一次感染症の終了及び／又は病理学的兆候及び／又は症状を認めなくなってから５～１２日後に発生する感染症でもあり得る。 In the present invention, secondary infection means primary infection and/or inflammation and/or any infection that may occur after surgery. For example, it can be an infection that occurs 1 to 28 days after the onset of the primary infection, eg, 5 to 12 days after the onset of the primary infection. It may also be an infection that occurs , for example, 1 to 21 days after the end of the primary infection, for example 5 to 12 days after the end of the primary infection and/or the disappearance of pathological signs and/or symptoms .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023124635A JP2023175677A (en) | 2017-07-17 | 2023-07-31 | Interleukin 12 (il12) or derivative thereof for use in treatment of secondary disease |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305945 | 2017-07-17 | ||
| EP17305945.2 | 2017-07-17 | ||
| EP17201074.6 | 2017-11-10 | ||
| EP17201074 | 2017-11-10 | ||
| PCT/EP2018/069190 WO2019016109A1 (en) | 2017-07-17 | 2018-07-16 | Interleukin 12 (il12) or derivative thereof for use in the treatment of secondary disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023124635A Division JP2023175677A (en) | 2017-07-17 | 2023-07-31 | Interleukin 12 (il12) or derivative thereof for use in treatment of secondary disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527153A JP2020527153A (en) | 2020-09-03 |
| JP2020527153A5 JP2020527153A5 (en) | 2021-08-26 |
| JPWO2019016109A5 true JPWO2019016109A5 (en) | 2024-01-24 |
Family
ID=62904494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502446A Pending JP2020527153A (en) | 2017-07-17 | 2018-07-16 | Interleukin 12 (IL12) or its derivatives for use in the treatment of secondary diseases |
| JP2023124635A Pending JP2023175677A (en) | 2017-07-17 | 2023-07-31 | Interleukin 12 (il12) or derivative thereof for use in treatment of secondary disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023124635A Pending JP2023175677A (en) | 2017-07-17 | 2023-07-31 | Interleukin 12 (il12) or derivative thereof for use in treatment of secondary disease |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200147177A1 (en) |
| EP (1) | EP3655016A1 (en) |
| JP (2) | JP2020527153A (en) |
| WO (1) | WO2019016109A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016203A1 (en) * | 1995-11-01 | 1997-05-09 | Genetics Institute, Inc. | Methods for administration of il-12 |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| CN1942201B (en) * | 2004-02-17 | 2012-06-20 | 先灵公司 | Methods of modulating cytokine activity, related reagents |
| EP2854777B1 (en) * | 2012-05-29 | 2016-12-28 | The Research Foundation for the State University of New York | Combined therapy and prophylaxis for genital tract infections |
| US20160022777A1 (en) * | 2014-07-28 | 2016-01-28 | Nkt Therapeutics Inc. | Combination therapy with il-12 |
-
2018
- 2018-07-16 WO PCT/EP2018/069190 patent/WO2019016109A1/en unknown
- 2018-07-16 US US16/631,687 patent/US20200147177A1/en not_active Abandoned
- 2018-07-16 JP JP2020502446A patent/JP2020527153A/en active Pending
- 2018-07-16 EP EP18740226.8A patent/EP3655016A1/en active Pending
-
2023
- 2023-07-31 JP JP2023124635A patent/JP2023175677A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119389A1 (en) | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
| SE9802333D0 (en) | Novel combination | |
| DK1307189T3 (en) | Use of hydroxyethyl rutosides for the treatment of cold symptoms, allergic rhinitis and respiratory tract infections | |
| ECSP088390A (en) | METHOD FOR PREVENTIVE HORMONAL ANTI-CONCEPTION UNDER DEMAND | |
| AR054428A1 (en) | COMPOSITIONS OF ANTIBODIES ANTI FACTOR OF COLOGNE OF MACROFAGOS (ANTI-M-CSF) THAT HAVE LOWER LEVELS OF ENDOTOXIN | |
| HUP0400659A2 (en) | Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease | |
| Goswami et al. | A prospective study to evaluate safety, efficacy and expulsion rate of post placental insertion of intra uterine device | |
| UY29779A1 (en) | NITROOXI DERIVED FROM STEROIDS | |
| CY1114133T1 (en) | Substituted c-phenyl-D-lactams and their related uses | |
| Ikeako et al. | Pattern and outcome of induced abortion in Abakaliki, Southeast of Nigeria | |
| EP4389209A3 (en) | Fecal microbiota composition, for use in reducing treatment-induced inflammation | |
| MA49839B1 (en) | Bicyclic histone deacetylase inhibitors | |
| CL2024000829A1 (en) | Solid forms of a ge glyt1 inhibitor | |
| UY31325A1 (en) | COMPOSITIONS AND METHODS TO TREAT IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | |
| EA202190310A1 (en) | PROTEIN FOR INFLAMMATORY DISEASES | |
| BR112022005883A2 (en) | Fluoride-free anticaries oral treatment compositions | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| BR112022020020A2 (en) | METHODS OF TREATMENT OF CORONAVIRUS DISEASE 2019 | |
| JPWO2019016109A5 (en) | ||
| Asnani et al. | Study of knowledge, attitude, practices regarding PPIUCD among antenatal women at a tertiary care centre in Northern India | |
| WO2007064859A3 (en) | Compound and method for suppressing retroviral replication | |
| Mahmood et al. | Efficacy of nasal splints in reducing the incidence of intranasal adhesions following septoplasty | |
| WO2022113071A3 (en) | Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity | |
| WO2008024543A3 (en) | Method of using composition comprising pomegranate extracts against influenza | |
| HUP0203321A2 (en) | 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation |